Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD)’s Entry Into Cancer Therapy

Page 1 of 2

It is interesting to watch a bio company change tactics and go into an area it hasn’t explored before. This, to me, is like watching a child suddenly grow up. For a startup to thrive in this sector, it takes a lot of patience and focus. Investors cannot give a pre-developmental bio company enough money to diversify. Only when a company grows and starts making money out of its initial products does it develop the wherewithal to divert into different specialties. It ceases to be a struggling small biotech and becomes a conglomerate. That is when the company grows up.

Although that is not absolutely true of Gilead Sciences, Inc. (NASDAQ:GILD), a market leader in HIV medications, I am intrigued that it entered into the highly competitive oncology market already dominated by the world’s leading players such as Novartis AG (ADR) (NYSE:NVS), Roche (NASDAQOTH: RHHBY) and Pfizer Inc. (NYSE:PFE).

Gilead Sciences, Inc. (NASDAQ:GILD)

The company is currently focusing on leukemia and other blood cancers with a series of product candidates involving different mechanisms. Currently, most of the products are in clinical stages, including Idelalisib in Phase III for blood cancer and Simtuzumab in Phase II for pancreatic and colorectal cancer.


Products/Product candidates Mechanism of action Indications Status
Oncology Idelalisib PI3K delta inhibitor Chronic Lymphocytic Leukemia Phase III
Idelalisib PI3K delta inhibitor Indolent non-Hodgkin’s Lymphoma Phase III
Momelotinib JAK inhibitor Myelofibrosis Phase II
Simtuzumab monoclonal antibody Myelofibrosis Phase II
Simtuzumab monoclonal antibody Pancreatic Cancer Phase II
Simtuzumab monoclonal antibody Colorectal Cancer Phase II
GS-9973 Syk inhibitor B-Cell Malignancies Phase II
GS-9820 PI3K delta inhibitor Lymphoid Malignancies Phase II
GS-5745 MMP9 mAb inhibitor Solid Tumors Phase I

Source: Gilead annual report

Idelalisib, an experimental drug from Gilead Sciences, Inc. (NASDAQ:GILD), blocks the PI3 Kinase delta (a subtype of PI3K proteins) function that is primarily responsible for tumor growth in patients with chronic lymphocytic leukemia and indolent non-Hodgkin’s Lymphoma. Chronic lymphocytic leukemia, also known as CLL, is a blood and bone-marrow disease that usually grows slowly. It mostly occurs in adults rather than children.

Interestingly, in 2010, chronic lymphocytic leukemia dominated the blood-cancer market compared to acute lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. However, it is expected that the market will equally be distributed across all forms of blood cancer by 2020. In 2010, North America alone contributed nearly 62% of the total sales of leukemia drugs of which Gleevec, the market leader, comprised of around 56% of total sales.

Currently, Novartis, GlaxoSmithKline plc (ADR) (NYSE:GSK), Roche, Bristol Myers Squibb Co. (NYSE:BMY), Celgene Corporation (NASDAQ:CELG) and Biogen Idec Inc. (NASDAQ:BIIB) are the key players in the leukemia market. This market is still under-served due to increasing unmet needs and limited treatment options available for larger populations. Therefore, it is expected that the Leukemia market will grow at a compound annual growth rate of 3.84% from 2015 to 2020. This will provide an opportunity for Gilead Sciences, Inc. (NASDAQ:GILD) in the CLL market as most companies aim at novel products with higher efficacy for the treatment of CLL.

Fundamentally, Gilead Sciences, Inc. (NASDAQ:GILD) is strong in its performance with a solid product portfolio in the anti-viral segment. In the first quarter of 2013, Gilead Sciences, Inc. (NASDAQ:GILD) reported revenue of $2.53 billion, up 11% compared to $2.28 billion during the first quarter of 2012. This was due to 8% year-over-year growth in overall product sales, which again resulted from increased anti-viral and cardiovascular product sales. Anti-viral products alone contributed 86% of total product sales.


In the first quarter of 2013, anti-viral products reported sales of $2.06 billion, up by 7% compared to 2012. This was due to: a) strong demand in Complera and Stribild; b) a significant rise in Viread sales; partly offsetting a 8% decline in sales of Truvada.


Also, non-GAAP net income during the first quarter of 2013 was $801.9 million or $0.48 per diluted share compared to $704.4 million or $0.45 per diluted share during the same quarter in 2012.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!